Key Insights

Highlights

Success Rate

94% trial completion (above average)

Published Results

12 trials with published results (29%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

4.8%

2 terminated out of 42 trials

Success Rate

94.3%

+7.8% vs benchmark

Late-Stage Pipeline

62%

26 trials in Phase 3/4

Results Transparency

36%

12 of 33 completed with results

Key Signals

12 with results94% success

Data Visualizations

Phase Distribution

38Total
Not Applicable (4)
P 1 (4)
P 2 (4)
P 3 (18)
P 4 (8)

Trial Status

Completed33
Unknown3
Recruiting2
Terminated2
Active Not Recruiting1
Not Yet Recruiting1

Trial Success Rate

94.3%

Benchmark: 86.5%

Based on 33 completed trials

Clinical Trials (42)

Showing 20 of 20 trials
NCT02615184Phase 2TerminatedPrimary

A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

NCT05267613Phase 3Active Not RecruitingPrimary

Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.

NCT05890001Phase 3Completed

A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease

NCT05587309Phase 3CompletedPrimary

A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis

NCT04255693Not ApplicableRecruiting

Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adherence

NCT06660342RecruitingPrimary

A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring

NCT06391177Phase 1CompletedPrimary

A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily

NCT01499368Phase 3CompletedPrimary

A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients

NCT06720610Phase 4Not Yet RecruitingPrimary

Indonesian Study of Vonoprazan Vs Esomeprazole in Erosive Esophagitis

NCT05443984Phase 3CompletedPrimary

JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

NCT05050188Phase 1CompletedPrimary

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008

NCT02679508Phase 4CompletedPrimary

Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety

NCT05055128Phase 2CompletedPrimary

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

NCT04124926Phase 3CompletedPrimary

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis

NCT04888819Not ApplicableUnknownPrimary

Treatment Effect According to Timing of Administration of DWP14012 40 mg

NCT03943992Phase 3CompletedPrimary

Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD)

NCT04613895Not ApplicableUnknownPrimary

Treatment Effect According to Timing of Administration of DWP14012 40 mg

NCT03736369Phase 3CompletedPrimary

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)

NCT02388737Phase 3CompletedPrimary

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis

NCT02388724Phase 3CompletedPrimary

Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis

Scroll to load more

Research Network

Activity Timeline